FDA lifts partial clinical hold on Mersana’s Phase l study of XMT-1522
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on a Phase l study initiated by…
XMT-1522 Mersana Therapeutics FDA
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on a Phase l study initiated by…